Changes will give NHS patients ‘quicker access to new medicines’
The body said that its proposals, which are expected to be approved by its board on Wednesday, will make patient access to new treatments ‘fairer’.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Changes to the way medicines and devices are assessed for NHS use in England will give patients “better access to life-changing medicines”, experts have said.
The National Institute for Health and Care Excellence (Nice) has proposed a raft of measures changing the way that it assesses new medicines and devices for NHS use.
The body said that its proposals, which are expected to be approved by its board on Wednesday, will make patient access to new treatments “fairer”.
If approved, Nice said that the measures would give patients quicker access to new treatments because those assessing them will have greater flexibility in decision making.
The changes being discussed will provide a robust foundation for our evaluations now and in the future and enable us to continue to lead the way in rapid, independent health technology assessments
Those making decisions about which treatments should be available on the NHS will also give greater weight to the lived experiences of patients.
Nice chief executive Professor Gillian Leng said: “Our vision at Nice is to be at the forefront of delivering access for patients in the NHS to valuable, evidence-based innovative medicines, medical devices and diagnostics.
“The changes being discussed will provide a robust foundation for our evaluations now and in the future and enable us to continue to lead the way in rapid, independent health technology assessments.”
Commenting on the reforms, Paul Catchpole from the Association of the British Pharmaceutical Industry said: “The changes set to be approved will help support better access to life-changing medicines.
“We share Nice’s ambition for fairness and equity of access to the latest medicines, including those for rare diseases.”